Ivermectin in COVID 19

Published: 2 February 2022| Version 1 | DOI: 10.17632/ppg255h3bj.1
Contributor:
Thananda Trakarnvanich

Description

A randomized, double-blind, placebo-controlled trial of ivermectin, an antiparasitic drug, for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in hospitalized adult patients (aged 18–80 years) between July 1, 2021 and October 31, 2021.

Files

Categories

COVID-19

Licence